Drug Approval | August 02, 2021
Clinical trials in the UK to study the efficacy of Ashwagandha on COVID 19 patients
Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine
Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine
Turnover of API division of ISLL stood at Rs 856.58 crore
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
Price band in the range of Rs 933 to Rs 954
The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
Earlier, the USFDA has granted ‘Orphan Drug Designation’ and ‘Fast Track Designation’ to Saroglitazar Mg for PBC
The US FDA has closed the observations pertaining to this audit with an Establishment Inspection Report on the 20th of July 2021
State-of-the-art R&D lab expands technical feasibility capabilities for long-acting delivery of small molecules, biologics, nucleotides
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
Subscribe To Our Newsletter & Stay Updated
